<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01540799</url>
  </required_header>
  <id_info>
    <org_study_id>Pathway M-1 (CIP-003)</org_study_id>
    <nct_id>NCT01540799</nct_id>
  </id_info>
  <brief_title>Pathway M-1: Sphenopalatine Ganglion Stimulation for the AcuteTreatment of High Disability Migraine Headache</brief_title>
  <acronym>Pathway M-1</acronym>
  <official_title>Pathway M-1: Sphenopalatine Ganglion Stimulation for the AcuteTreatment of High Disability Migraine Headache</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Autonomic Technologies, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Autonomic Technologies, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the clinical study is to evaluate the use of an implanted sphenopalatine
      ganglion (SPG) neurostimulator for the treatment of migraine headache pain, migraine headache
      symptoms and migraine frequency in high disability migraineurs.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>February 2012</start_date>
  <completion_date type="Anticipated">July 2017</completion_date>
  <primary_completion_date type="Anticipated">July 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Major Device- and Surgical-Related Complications</measure>
    <time_frame>Implantation through completion of Experimental Period (18 weeks following the implantation procedure)</time_frame>
    <description>Occurrence rate of death, any surgery or hospitalization due to deterioration in subject health, or other Major Device-related Adverse Events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Effective Therapy</measure>
    <time_frame>During Experimental Period (12 to 18 weeks following implantation)</time_frame>
    <description>Number of Migraine Pain Days during the Experimental Period, compared between the Treatment and Control arms.
Migraine Pain Day is any calendar day that:
Has less than 4 hours of moderate or severe pain meeting criteria C and D for migraine ICHD-II 1.1 AND
No Acute Headache or Migraine Pain Medication (pharmacologic medications, not including SPG stimulation, used to treat acute headache pain).
AND
No SPG stimulation is applied for headache pain of any intensity</description>
  </primary_outcome>
  <other_outcome>
    <measure>Number of Migraine Free Days during the Experimental Period, compared between the Treatment and Control arms.</measure>
    <time_frame>During Experimental Period (12 to 18 weeks following implantation)</time_frame>
    <description>Migraine Free Day is any calendar day that:
Has less than 4 hours of moderate or severe pain meeting criteria C and D for migraine ICHD-II 1.1 AND
No Acute Headache or Migraine Pain Medication is used AND
No SPG stimulation is applied for headache pain of any intensity</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of Headache Free Days during the Experimental Period, compared between the Treatment and Control arms</measure>
    <time_frame>During Experimental Period (12 to 18 weeks following implantation)</time_frame>
    <description>Headache Free Day is any calendar day that:
Has less than 4 hours of moderate or severe pain AND
No Acute Headache or Migraine Pain Medication is used AND
No SPG stimulation is applied for headache pain of any intensity</description>
  </other_outcome>
  <other_outcome>
    <measure>Percent change in number of Migraine Free Days during the last 4 weeks of the Experimental Period relative to the 4 weeks preceding the implantation procedure, compared between the Treatment and Control arms</measure>
    <time_frame>During Experimental Period (14 to 18 weeks following implantation) compared to Baseline</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Percent change in number of Headache Free Days during the last 4 weeks of the Experimental Period relative to the 4 weeks preceding the implantation procedure, compared between the Treatment and Control arms</measure>
    <time_frame>During Experimental Period (14 to 18 weeks following implantation) compared to Baseline</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Descriptive responder analysis of Migraine Free Days during the Experimental Period relative to the Pre-Implant Baseline</measure>
    <time_frame>During Experimental Period (12 to 18 weeks following implantation) compared to Baseline</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Descriptive responder analysis of Headache Free Days during the Experimental Period relative to the Pre-Implant Baseline</measure>
    <time_frame>During Experimental Period (12 to 18 weeks following implantation) compared to Baseline</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Proportion of subjects who achieve Pain Relief at 4 hours in at least 50% of their moderate/severe SPG stimulation treated attacks during the Experimental Period</measure>
    <time_frame>During Experimental Period (12 to 18 weeks following implantation)</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Proportion of subjects who achieve Pain Relief at 2 hours in at least 50% of their moderate/severe SPG stimulation treated attacks during the Experimental Period</measure>
    <time_frame>During Experimental Period (12 to 18 weeks following implantation)</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Proportion of subjects who achieve Pain Freedom at 4 hours in at least 50% of their moderate/severe SPG stimulation treated attacks during the Experimental Period</measure>
    <time_frame>During Experimental Period (12 to 18 weeks following implantation)</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Proportion of subjects who achieve Pain Freedom at 2 hours in at least 50% of their moderate/severe SPG stimulation treated attacks during the Experimental Period</measure>
    <time_frame>During Experimental Period (12 to 18 weeks following implantation)</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Proportion of subjects who achieve Pain Freedom at 4 hours in at least 50% of their mild SPG stimulation treated attacks during the Experimental Period</measure>
    <time_frame>During Experimental Period (12 to 18 weeks following implantation)</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Proportion of subjects who achieve Pain Freedom at 2 hours in at least 50% of their mild SPG stimulation treated attacks during the Experimental Period</measure>
    <time_frame>During Experimental Period (12 to 18 weeks following implantation)</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Descriptive analysis of associated symptoms [i.e., photophobia, phonophobia, nausea/vomiting, autonomic symptoms] relief at 4 hours, evaluated for relief of each symptom individually and for relief of all symptoms</measure>
    <time_frame>During Experimental Period (12 to 18 weeks following implantation)</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Disability and Quality of Life as categorized by the HIT-6, MIDAS and SF-36v2 surveys administered at the end of the Experimental Period, compared between the Treatment and Control arms</measure>
    <time_frame>End of Experimental Period (18 weeks following implantation)</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Descriptive responder analysis of Disability and Quality of Life as categorized by the HIT-6, MIDAS and SF-36v2 surveys relative to the Pre-Implant Baseline survey responses</measure>
    <time_frame>End of Experimental Period (18 weeks following implantation) compared to Baseline</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Global patient evaluation of SPG stimulation therapy (very poor, poor, no opinion, good, very good) administered at the end of the Experimental Period, compared between the Treatment and Control arms</measure>
    <time_frame>End of Experimental Period (18 weeks following implantation)</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Use of preventive medications during the Open Label Period as compared to Baseline, evaluated in all subjects</measure>
    <time_frame>During Open Label Period (18 to 52 weeks following implantation) compared to Baseline</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Use of acute medications during the Experimental Period as compared between the Treatment and Control arms</measure>
    <time_frame>During Experimental Period (12 to 18 weeks following implantation)</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Use of acute medications during the Open Label Period as compared to Baseline, evaluated in all subjects</measure>
    <time_frame>During Open Label Period (18 to 52 weeks following implantation) compared to Baseline</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>High Frequency, High Disability Migraine</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Other</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Stimulation not able to be felt</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ATI Neurostimulation System</intervention_name>
    <description>ATI Neurostimulator (NS-100) and Remote Controller (RC-200)</description>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_label>Other</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age â‰¥ 18 years old.

          -  Subject has been diagnosed at least 3 months prior to study enrollment with migraine
             headache with or without aura according to the 2004 ICHD-II criteria 1.1 or 1.2.1.1.

          -  Subject reports at least 75% of migraine attacks having predominantly fixed (non
             side-shifting) unilateral temporal or ocular pain.

          -  Subject reports that moderate/severe migraine pain is typically preceded by a mild
             pain phase.

          -  Subject reports a minimum of 8 days per month and a maximum of 14 days per month with
             migraine attacks of at least moderate severity based on the subject/Investigator's
             knowledge for at least 3 months prior to inclusion and confirmed for at least 1 month
             during the Pre-Implant Baseline Period using the Pathway M-1 Daily Headache Diary.

          -  Subject reports at least 24 hours of pain-free periods between typical migraine
             attacks.

          -  Subject has a MIDAS grade of III or IV, or has a HIT-6 score &gt; 56.

          -  Subject is medically intractable in the opinion of the Investigator.

          -  Subject has had stable type and dosage of preventive headache medications for at least
             1 month prior to study enrollment and agrees to maintain stable type and dosage of
             preventive headache medications through the completion of the Experimental Period.

          -  Subject is able to distinguish migraine attacks from other headaches (i.e., TTH).

          -  Subject agrees to not participate in supplemental or alternative therapy through the
             Open Label phase of the study. This includes: acupuncture, spinal manipulation, TENS,
             and magnetic fields treatments.

          -  Subject has the ability to read, comprehend, and to reliably record information as
             required by the Protocol.

          -  Subject is able to provide written informed consent prior to participation in the
             study.

        Exclusion Criteria:

          -  Subject's overall health, age and/or comorbidities place subject at high risk for
             complications from surgery and/or general anesthesia.

          -  Subject has been diagnosed with chronic migraine during the last year according to
             2006 ICHD-IIR Appendix 1.5.1.

          -  Subject currently has Medication Overuse Headache (MOH) or has a history of MOH during
             the last year according to the ICHD-2R 2006 criteria.

          -  Subject has used any triptans, pain medications or analgesics of any kind for any
             indication on more than 14 days per month over the last three months.

          -  Subject reports continuous daily headaches for one month or longer at time of consent.

          -  Subject reports initial onset of migraines within the last year.

          -  Subject has undergone facial surgery or has metallic implants in the area of the
             pterygopalatine fossa or zygomaticomaxillary buttress ipsilateral to the planned
             implant site that, in the opinion of the Investigator, may lead to the inability to
             properly implant or use the Neurostimulator.

          -  Subject has active oral or dental abscess.

          -  Subject has been treated with therapeutic radiation to the facial region.

          -  Subject has been diagnosed with any major infectious processes such as osteomyelitis,
             or primary or secondary malignancies involving the face that have been active or
             required treatment in the past 6 months or require periodic MRI follow-up.

          -  Subject's pterygomaxillary fissure is less than 1.2 mm in width at the level of the
             vidian canal, as determined by CT scan.

          -  Subject has clinically significant drug (including opioid) or alcohol abuse as defined
             by DSM-IV-TR, will likely be unable to refrain from substance abuse throughout the
             study, has other significant pain problem, substance abuse or active depressive
             episode that might confound the study assessments in the opinion of the Investigator.

          -  Subject is currently participating or has participated in the last month in another
             clinical study in which the subject has, is, or will be exposed to an investigational
             drug or device.

          -  Subject is felt to be at risk of non-compliance (e.g., for completing the diary,
             maintaining a stable headache medicine regimen or returning for required follow-up
             visits) in the Investigator's opinion.

          -  Subject is a woman of childbearing age who is pregnant, nursing, or not using
             contraception. A sterilized or infertile woman is exempt from the requirement to use
             contraception.

          -  Subject has had previous lesional radiofrequency ablation of the ipsilateral
             sphenopalatine ganglion (SPG).

          -  Subject has had blocks or non-lesional pulsed RF of the ipsilateral SPG in the last 3
             months.

          -  Subject has undergone botulinium toxin injections of the head and/or neck in the last
             3 months.

          -  Subject has or requires a pacemaker/defibrillator or other implantable device having a
             sense amplifier that is programmed 'On.'

          -  Subject has a history of bleeding disorders or coagulopathy or is unable to
             discontinue anticoagulation, antiplatelet, or GP IIb IIIa inhibitor medication in
             preparation for the implantation procedure.

          -  Subject has a chronic neurological illness of the face (e.g., facial nerve paralysis,
             trigeminal neuralgia).

          -  Subject is not suitable for the study for any reason in the judgment of the
             Investigator.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rigmor Jensen, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Danish Headache Center, Glostrup Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dept. of Neurology, K12 Bldg. 1st fl, De Pintelaan 185 B-9000</name>
      <address>
        <city>Ghent</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Danish Headache Center &amp; Department of Neurology, Glostrup Hospital, University of Copenhagen</name>
      <address>
        <city>Glostrup</city>
        <state>Copenhagen</state>
        <zip>DK-2600</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Servicio de Neurologia, Hospital Clinico Universitario</name>
      <address>
        <city>Valencia</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Denmark</country>
    <country>Spain</country>
  </location_countries>
  <removed_countries>
    <country>France</country>
  </removed_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 20, 2012</study_first_submitted>
  <study_first_submitted_qc>February 28, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 29, 2012</study_first_posted>
  <last_update_submitted>May 23, 2017</last_update_submitted>
  <last_update_submitted_qc>May 23, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 25, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Migraine</keyword>
  <keyword>High disability migraine</keyword>
  <keyword>Sphenopalatine ganglion</keyword>
  <keyword>Neuromodulation</keyword>
  <keyword>Neurostimulation</keyword>
  <keyword>Autonomic nervous system</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Migraine Disorders</mesh_term>
    <mesh_term>Headache</mesh_term>
    <mesh_term>Ganglion Cysts</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

